Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-12-2021 | Positron Emission Tomography | Review Article

Long axial field of view PET scanners: a road map to implementation and new possibilities

Authors: Riemer H. J. A. Slart, Charalampos Tsoumpas, Andor W. J. M. Glaudemans, Walter Noordzij, Antoon T. M. Willemsen, Ronald J. H. Borra, Rudi A. J. O. Dierckx, Adriaan A. Lammertsma

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 13/2021

Abstract

In this contribution, several opportunities and challenges for long axial field of view (LAFOV) PET are described. It is an anthology in which the main issues have been highlighted. A consolidated overview of the camera system implementation, business and financial plan, opportunities and challenges is provided. What the nuclear medicine and molecular imaging community can expect from these new PET/CT scanners is the delivery of more comprehensive information to the clinicians for advancing diagnosis, therapy evaluation and clinical research.

Phelps ME, Hoffman EJ, Huang SC, Kuhl DE. ECAT: a new computerized tomographic imaging system for positron-emitting radiopharmaceuticals. J Nucl Med. 1978;19(6):635–47.PubMed

Jones T, Rabiner EA, Company PETRA. The development, past achievements, and future directions of brain PET. J Cereb Blood Flow Metab. 2012;32(7):1426–54.CrossRef

Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med. 1986;314(14):884–8.CrossRef

Wagner HN Jr. Clinical PET: its time has come. J Nucl Med. 1991;32(4):561–4.PubMed

Dahlbom M, Hoffman EJ, Hoh CK, Schiepers C, Rosenqvist G, Hawkins RA, et al. Whole-body positron emission tomography: part I. Methods and performance characteristics. J Nucl Med. 1992;33(6):1191–9.PubMed

Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343(4):254–61.CrossRef

van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359(9315):1388–93.CrossRef

van Sluis J, Boellaard R, Dierckx R, Stormezand GN, Glaudemans A, Noordzij W. Image quality and activity optimization in oncologic (18)F-FDG PET using the digital biograph vision PET/CT system. J Nucl Med. 2020;61(5):764–71.CrossRef

van der Vos CS, Koopman D, Rijnsdorp S, Arends AJ, Boellaard R, van Dalen JA, et al. Quantification, improvement, and harmonization of small lesion detection with state-of-the-art PET. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):4–16.PubMedPubMedCentral

10.

Cheebsumon P, Velasquez LM, Hoekstra CJ, Hayes W, Kloet RW, Hoetjes NJ, et al. Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis. Eur J Nucl Med Mol Imaging. 2011;38(5):832–42.CrossRef

11.

Bahce I, Smit EF, Lubberink M, van der Veldt AA, Yaqub M, Windhorst AD, et al. Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status. Clin Cancer Res. 2013;19(1):183–93.CrossRef

12.

Lammertsma AA. Forward to the past: the case for quantitative PET imaging. J Nucl Med. 2017;58(7):1019–24.CrossRef

13.

Cherry SR, Jones T, Karp JS, Qi J, Moses WW, Badawi RD. Total-body PET: maximizing sensitivity to create new opportunities for clinical research and patient care. J Nucl Med. 2018;59(1):3–12.CrossRef

14.

Webpage. https://msis.jsc.nasa.gov/sections/section03.htm.

15.

Alberts I, Hunermund JN, Prenosil G, Mingels C, Bohn KP, Viscione M, et al. Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT. Eur J Nucl Med Mol Imaging. 2021.

16.

Badawi RD, Shi H, Hu P, Chen S, Xu T, Price PM, et al. First human imaging studies with the EXPLORER total-body PET scanner. J Nucl Med. 2019;60(3):299–303.CrossRef

17.

Abgral R, Bourhis D, Salaun P-Y. Clinical perspectives for the use of total body PET/CT. Eur J Nucl Med Mol Imaging. 2021;48(6):1712–8. https://doi.org/10.1007/s00259-021-05293-4.CrossRefPubMed

18.

Lennon AM, Buchanan AH, Kinde I, Warren A, Honushefsky A, Cohain AT, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science. 2020;369(6499):eabb9601. https://doi.org/10.1126/science.abb9601.CrossRefPubMedPubMedCentral

19.

Beason-Held LL, Goh JO, An Y, Kraut MA, O’Brien RJ, Ferrucci L, Resnick SM. Changes in brain function occur years before the onset of cognitive impairment. J Neurosci. 2013;33(46):18008–14.CrossRef

20.

Zhao YM, Li YH, Chen T, Zhang WG, Wang LH, Feng J, et al. Image quality and lesion detectability in low-dose pediatric (18)F-FDG scans using total-body PET/CT. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05304-4.

21.

Matthews PM, Rabiner EA, Passchier J, Gunn RN. Positron emission tomography molecular imaging for drug development. Br J Clin Pharmacol. 2012;73(2):175–86.CrossRef

22.

Borghammer P, Van Den Berge N. Brain-first versus gut-first Parkinson’s disease: a hypothesis. J Parkinsons Dis. 2019;9(s2):S281–95.CrossRef

23.

Willyard C. How gut microbes could drive brain disorders. Nature. 2021;590(7844):22–5.CrossRef

24.

Zhu S, Jiang Y, Xu K, Cui M, Ye W, Zhao G, et al. The progress of gut microbiome research related to brain disorders. J Neuroinflammation. 2020;17(1):25.CrossRef

25.

Fedorova TD, Seidelin LB, Knudsen K, Schacht AC, Geday J, Pavese N, et al. Decreased intestinal acetylcholinesterase in early Parkinson disease: An (11)C-donepezil PET study. Neurology. 2017;88(8):775–81.CrossRef

26.

Knudsen K, Fedorova TD, Hansen AK, Sommerauer M, Otto M, Svendsen KB, et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol. 2018;17(7):618–28.CrossRef

27.

Gargiulo S, Anzilotti S, Coda AR, Gramanzini M, Greco A, Panico M, et al. Imaging of brain TSPO expression in a mouse model of amyotrophic lateral sclerosis with (18)F-DPA-714 and micro-PET/CT. Eur J Nucl Med Mol Imaging. 2016;43(7):1348–59.CrossRef

28.

Segarra AB, Prieto I, Martinez-Canamero M, Ramirez-Sanchez M. Is there a link between depression, neurochemical asymmetry and cardiovascular function? AIMS Neurosci. 2020;7(4):360–72.CrossRef

29.

Rosen SD, Paulesu E, Frith CD, Frackowiak RS, Davies GJ, Jones T, et al. Central nervous pathways mediating angina pectoris. Lancet. 1994;344(8916):147–50.CrossRef

30.

Bascunana P, Hess A, Borchert T, Wang Y, Wollert KC, Bengel FM, et al. (11)C-Methionine PET identifies astroglia involvement in heart-brain inflammation networking after acute myocardial infarction. J Nucl Med. 2020;61(7):977–80.CrossRef

31.

Tawakol A, Ishai A, Takx RA, Figueroa AL, Ali A, Kaiser Y, et al. Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. Lancet. 2017;389(10071):834–45.CrossRef

32.

Sposato LA, Hilz MJ, Aspberg S, Murthy SB, Bahit MC, Hsieh CY, et al. Post-stroke cardiovascular complications and neurogenic cardiac injury: JACC state-of-the-art review. J Am Coll Cardiol. 2020;76(23):2768–85.CrossRef

33.

Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22(4):584–603.CrossRef

34.

Pijl JP, Glaudemans A, Slart R, Yakar D, Wouthuyzen-Bakker M, Kwee TC. FDG-PET/CT for detecting an infection focus in patients with bloodstream infection: factors affecting diagnostic yield. Clin Nucl Med. 2019;44(2):99–106.CrossRef

35.

Pijl JP, Kwee TC, Slart R, Glaudemans A. PET/CT imaging for personalized management of infectious diseases. J Pers Med. 2021;11(2):133. https://doi.org/10.3390/jpm11020133.CrossRefPubMedPubMedCentral

36.

Tsoumpas C. Why ultrafast is ultra-good. Physics World. 2020;33(6):41–4.CrossRef

37.

Zhang X, Cherry SR, Xie Z, Shi H, Badawi RD, Qi J. Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci U S A. 2020;117(5):2265–7.CrossRef

38.

Jones T. Total body PET imaging from mice to humans. Frontiers in Phys. 2020;8(77):4.

39.

Feng T, Zhao Y, Shi H, Li H, Zhang X, Wang G, Badawi RD, et al. Total-body quantitative parametric imaging of early kinetics of 18 F-FDG. J Nucl Med. 2020;62(5):738–44. https://doi.org/10.2967/jnumed.119.238113.CrossRefPubMed

40.

Cherry SR, Badawi RD, Karp JS, Moses WW, Price P, Jones T. Total-body imaging: transforming the role of positron emission tomography. Sci Transl Med. 2017;9(381):eaaf6169. https://doi.org/10.1126/scitranslmed.aaf6169.CrossRefPubMedPubMedCentral

41.

Nardo L, Schmall JP, Werner TJ, Malogolowkin M, Badawi RD, Alavi A. Potential roles of total-body PET/computed tomography in pediatric imaging. PET Clin. 2020;15(3):271–9.CrossRef

42.

Zanotti-Fregonara P, Lammertsma AA, Innis RB. Suggested pathway to assess radiation safety of (1)(8)F-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging. 2013;40(11):1781–3.CrossRef

43.

Zanotti-Fregonara P, Lammertsma AA, Innis RB. 11 C dosimetry scans should be abandoned. J Nucl Med. 2021;62(2):158–9. https://doi.org/10.2967/jnumed.120.257402.CrossRefPubMed

44.

Simoncic U, Perlman S, Liu G, Jeraj R. Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancer. Nucl Med Commun. 2015;36(12):1174–80.CrossRef

45.

Vandenberghe S, Moskal P, Karp JS. State of the art in total body PET. EJNMMI Phys. 2020;7(1):35.CrossRef

46.

van Sluis J, Boellaard R, Somasundaram A, van Snick PH, Borra RJH, Dierckx R, et al. Image quality and semiquantitative measurements on the Biograph Vision PET/CT system: initial experiences and comparison with the Biograph mCT. J Nucl Med. 2020;61(1):129–35.CrossRef

47.

Planning a clinical PET centre Vienna: International atomic energy agency. 2010. [Available from: https://www-pub.iaea.org/MTCD/publications/PDF/Pub1457_web.pdf.

48.

Rosslyn VA. National Electrical Manufacturers Association performance measurements of positron emission tomographs. National Electrical Manufacturers Association NEMA Standards Publication. 2012;NU-2.

49.

Rosslyn VA. National Electrical Manufacturers Association performance measurements of positron emission tomographs. . National Electrical Manufacturers Association; 2012 NEMA Standards Publication. 2018;NU 2.

50.

Rosslyn VANEMA. National Electrical Manufacturers Association performance measurements of positron emission tomographs. NEMA Standards Publication NU 2–2012. 2012.

51.

Meikle SR, Sossi V, Roncali E, Cherry SR, Banati R, Mankoff D, et al. Quantitative PET in the 2020s: a roadmap. Phys Med Biol. 2021;66(6):06RM1.CrossRef

52.

Sanabria-Bohorquez SM, Labar D, Leveque P, Bol A, De Volder AG, Michel C, et al. [11C]flumazenil metabolite measurement in plasma is not necessary for accurate brain benzodiazepine receptor quantification. Eur J Nucl Med. 2000;27(11):1674–83.CrossRef

Title: Long axial field of view PET scanners: a road map to implementation and new possibilities
Authors: Riemer H. J. A. Slart
Charalampos Tsoumpas
Andor W. J. M. Glaudemans
Walter Noordzij
Antoon T. M. Willemsen
Ronald J. H. Borra
Rudi A. J. O. Dierckx
Adriaan A. Lammertsma
Publication date: 01-12-2021
Publisher: Springer Berlin Heidelberg
Keyword: Positron Emission Tomography
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 13/2021
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05461-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Long axial field of view PET scanners: a road map to implementation and new possibilities

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 13/2021

Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging

Magnetic resonance fingerprinting: an overview

Quantitative impact of the first COVID-19 lockdown on nuclear medicine in France: the CORALINE study

Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging

Dynamic amino-acid PET in neuro-oncology: a prognostic tool becomes essential

Head-to-head comparison of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study